An excerpt from a recent paper (April 25, 2019) titled, Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease:
Biological results herein obtained place ent-1 and congeners among the earliest examples of l-iminosugars acting as anti-inflammatory agents for therapeutic applications in Cystic Fibrosis.
The paper describes how certain iminosugars were able to dramatically reduce the inflammatory response induced by P. aeruginosa… and do it extremely efficiently:
The remarkably low dosage [40-fold vs. counterpart] of the l-iminosugar, combined with its inability to act as inhibitor for most glycosidases, is expected to limit the onset of undesired effects, which are typically associated with the administration of its d-counterpart.
For more information, check out the recent paper (links below).
Further reading on iminosugars: